Qiagen (QGEN) reported $540.42 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 3.7%. EPS of $0.62 for the same period compares to $0.64 a year ago.
The reported revenue represents a surprise of +2.36% over the Zacks Consensus Estimate of $527.96 million. With the consensus EPS estimate being $0.62, the EPS surprise was +0.83%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Qiagen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Sales by Product Groups- Diagnostic solutions- QIAstat-Dx: $39 million compared to the $36.66 million average estimate based on four analysts. The reported number represents a change of +21.9% year over year.
- Sales by Product Groups- Diagnostic solutions- QuantiFERON: $123 million compared to the $128.51 million average estimate based on four analysts. The reported number represents a change of +6% year over year.
- Sales by Product Groups- Diagnostic solutions- Other: $40 million compared to the $37.47 million average estimate based on three analysts. The reported number represents a change of 0% year over year.
- Sales by Product Groups- Other: $18 million compared to the $15.71 million average estimate based on three analysts. The reported number represents a change of +20% year over year.
- Sales by Product Groups- PCR / Nucleic acid amplification: $78 million versus $80.01 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -4.9% change.
- Sales by Product Groups- Genomics / NGS: $69 million compared to the $70.74 million average estimate based on three analysts. The reported number represents a change of +4.6% year over year.
- Sales by Product Groups- Diagnostic solutions: $201 million versus the three-analyst average estimate of $202.71 million. The reported number represents a year-over-year change of +2.6%.
- Sales by Product Groups- Sample technologies: $175 million versus the three-analyst average estimate of $158.35 million. The reported number represents a year-over-year change of +8%.
View all Key Company Metrics for Qiagen here>>>
Shares of Qiagen have returned +4.9% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
QIAGEN N.V. (QGEN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
